Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. SPY
3. HUBS
4. NUE
5. AAPL
6. ONON
7. AZN
8. TRMD
9. NVDA
10. RARE

Go back to Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1147.07 -5.37 (0.47%)
Previous Close $1152.44    52 Week High $88.16 
Open $1150.00    52 Week Low $67.88 
Day High $1157.60    P/E 265.53 
Day Low $1141.00    EPS $4.32 
Volume 798,523